EXICURE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.49 USD | +1.45% |
|
-2.00% | -15.56% |
| Mar. 22 | North American Morning Briefing : Stocks Struggle After New Records | DJ |
| Feb. 29 | An unknown buyer agreed to acquire 39.3% stake in Exicure, Inc. from DGP Co.,Ltd. for KRW 6 billion. | CI |
Presenter SpeechDo Kim (Analysts)Good afternoon. My name is Do Kim, one of the biotech analyst...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.56% | 4.18M | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
- Stock Market
- Equities
- XCUR Stock
- News Exicure, Inc.
- Transcript : Exicure, Inc. Presents at BMO 2020 Prescriptions for Success Healthcare Conference, Jun-23-2020 04